Literature DB >> 1600055

Short report: twenty-four-hour hyperpepsinogenaemia in Helicobacter pylori-positive subjects is abolished by eradication of the infection.

A G Fraser1, E J Prewett, R E Pounder, I M Samloff.   

Abstract

Twenty-four-hour plasma pepsinogen I and II concentrations were determined in 8 healthy subjects with antibody to Helicobacter pylori, before and after treatment with tripotassium dicitrato bismuthate, amoxycillin and metronidazole, Therapy was successful in the 5 subjects with active H. pylori infection. In these subjects, median integrated 24-h plasma pepsinogen I and II concentrations significantly decreased from 2288 and 357 micrograms.h/L before treatment, respectively, to 1811 and 171 micrograms.h/L at 4-6 weeks after treatment, and 1643 and 150 micrograms.h/L at 20-24 weeks. By contrast, in the 3 subjects without evidence of active H. pylori infection, pre-treatment plasma pepsinogen I and II concentrations were similar to values found in the H. pylori-infected subjects after successful therapy, and they did not change significantly in response to therapy. H. pylori infection is associated with reversible hyperpepsinogenaemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1600055     DOI: 10.1111/j.1365-2036.1992.tb00060.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

1.  Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis.

Authors:  F M Hunter; P Correa; E Fontham; B Ruiz; M Sobhan; I M Samloff
Journal:  Dig Dis Sci       Date:  1993-11       Impact factor: 3.199

2.  Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens.

Authors:  A G Fraser; W M Lam; Y W Luk; J Sercombe; A M Sawyerr; M Hudson; I M Samloff; R E Pounder
Journal:  Gut       Date:  1993-03       Impact factor: 23.059

3.  Helicobacter pylori infection and serum pepsinogen I concentration in peptic ulcer patients: effect of bacterial eradication.

Authors:  S M Park; J Park; S K Chang; B C Yoo; H J Kim
Journal:  Korean J Intern Med       Date:  1996-01       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.